Filters
Results 1 - 10 of 5580
Results 1 - 10 of 5580.
Search took: 0.039 seconds
Sort by: date | relevance |
Hasegawa, Takeo; Gu, Yeun Hwa; Miyata, Katsuyuki; Hasegawa, Takashi; Tanaka, Yoshimasa; Takahashi, Tohru
Proceedings for the Korean Association for Radiation Protection Autumn Meeting1999
Proceedings for the Korean Association for Radiation Protection Autumn Meeting1999
AbstractAbstract
[en] The efficacy of hyperthermia for malignancies depend on various vasophsiological factors in the tumor, Such as pH, blood flow and oxygen tension. The present animal experiment was performed to ascertain how the effect of hyperthermia can be enhanced by administration of hydralazine (HYD), a vasodilator, which is known to decrease the local blood flow selectively and accordingly, decelerate thermal diffusion in the tumor. HYD (2-5mg/kg) was injected intraperitoneally 20 min before hyperthermia, which was done for 20-30 min at. 43 .deg. C by the use of a thermo-static water bath. The tumor quadrupling time was 4.5 days in the untreated FM3A group, 5.4 days in the HYD treated FM3A group, 8.5 days in the heat alone FM3A group and 11.2 days in the HYD plus heat treated FM3A group. Those in the respective SCC- VII group were 7.7 days, 9.0 days , 11.1 days and 14.0 days respectively. The enhancement ratio was 2.48 in the treatment for FM3A tumor and 1.81 in the treatment for SCC- VII tumor. Thus, these results indicate that HYD can increase the therapeutic efficiency of local hyperthermia treatment by inducing the change of microenvironment i.e. low pH, tumor hypoxia, deficient nutrition secondary to blood flow diminution which increase the sensitivity of tumor to heat
Primary Subject
Source
Korean Association for Radiation Protection, Seoul (Korea, Republic of); 301 p; 1999; p. 79-82; The Korean Association for Radiation Protection Autumn Meeting; Tague (Korea, Republic of); 22 Oct 1999; Available from KARP, Seoul (KR); 9 refs
Record Type
Miscellaneous
Literature Type
Conference
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] This paper reviews recent experience with drugs that have been found to increase blood flow in tumours and to sensitize them to radiation. (UK)
Primary Subject
Source
McNally, N.J. (ed.) (Mount Vernon Hospital, Northwood (UK). Gray Lab.); British Inst. of Radiology, London (UK); British Inst. of Radiology Report Series; no. 19; 149 p; ISBN 0-905749-20-0;
; 1989; p. 76-80; British Inst. of Radiology; London (UK); International symposium on the scientific basis of modern radiotherapy; Northwood (UK); 30 Jun - 2 Jul 1988

Record Type
Book
Literature Type
Conference
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Farris, G. Ross; Hage, Fadi G.; Kumar, Vineet; Iskandrian, Ami E., E-mail: Grfarris1@uabmc.edu2019
AbstractAbstract
No abstract available
Primary Subject
Source
Copyright (c) 2019 American Society of Nuclear Cardiology; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Journal of Nuclear Cardiology (Online); ISSN 1532-6551;
; v. 26(2); p. 684-687

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Short note
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Syntheses of |24-14C|3β,20xi-dihydroxy-23-norchol-5-enoic acid, |24-14C|3β20xi-dihydroxy-23-norcholanoic acid and |24-14C|20xi-hydroxy-3-oxo-23-norchol-4-enoic acid were accomplished by the reaction of ethyl |1-14C|bromoacetate in Reformatsky conditions, with suitable 20-keto-pregnane derivatives. Dehydration of these products afforded |24-14C|3β-hydroxy-23-norchola-5,20(22)E-dienoic acid, |24-14C|3β-hydroxy-23-norchol-20(22)E-enoic acid and |24-14C|3-oxo-23-norchola-4,20(22)E-dienoic acid respectively. The products were characterized by spectroscopic (IR, 1H NMR, MS) methods. (author)
Record Type
Journal Article
Journal
Journal of Labelled Compounds and Radiopharmaceuticals; ISSN 0362-4803;
; v. 22(5); p. 467-474

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
Figueredo, Rita C.R.; Sforca, Mauricio L.; Pertinhez, Thelma A.; Campos, Ana Carolina V.; Miranda, Antonio; Oliveira Junior, Vani X.; Spisni, Alberto
Proceedings of the 9. Meeting of the nuclear magnetic resonance users. Abstracts2003
Proceedings of the 9. Meeting of the nuclear magnetic resonance users. Abstracts2003
AbstractAbstract
No abstract available
Source
Associacao de Usuarios de Ressonancia Magnetica Nuclear, Rio de Janeiro, RJ (Brazil); 76 p; 2003; p. 58; 9. Meeting of the nuclear magnetic resonance users; 9. Encontro de usuarios de ressonancia magnetica nuclear; Angra dos Reis, RJ (Brazil); 5-9 May 2003; Available from the Library of the Brazilian Nuclear Energy Commission, Rio de Janeiro
Record Type
Miscellaneous
Literature Type
Conference
Country of publication
Reference NumberReference Number
Related RecordRelated Record
INIS VolumeINIS Volume
INIS IssueINIS Issue
Marra, M.; Fazio, M.A.; Miranda, A.; Oliveira Junior, V.X.
Sociedade Brasileira de Bioquimica e Biologia Molecular (SBBq), Sao Paulo, SP (Brazil)2008
Sociedade Brasileira de Bioquimica e Biologia Molecular (SBBq), Sao Paulo, SP (Brazil)2008
AbstractAbstract
No abstract available
Primary Subject
Source
2008; [1 p.]; 37. Annual meeting of the Brazilian Society on Biochemistry and Molecular Biology; Aguas de Lindoia, SP (Brazil); 17-20 May 2008; 11. Congress of the PABMB: Pan-American Association for Biochemistry and Molecular Biology; Aguas de Lindoia, SP (Brazil); 17-20 May 2008; Available from http://sbbq.iq.usp.br/arquivos/2008/cdlivro/resumos/R2244.pdf. Also available from the Nuclear Information Center of the Brazilian National Nuclear Energy Commission, Rio de Janeiro, in electronic form
Record Type
Miscellaneous
Literature Type
Conference
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] To compare antihypertensive effect of fixed dose combination Hydrochlorothiazide-Amiloride and Amlodipine in patients of mild essential hypertension. After fulfilling the inclusion criteria of mild essential hypertension, defined as per recommendations of Seventh Joint National Committee (JNC 7) for treatment of Hypertension as stage 1 hypertension, systolic blood pressure (SBP) amlodipine and hydrochlorthiazide-amiloride 140-159-mmHg and Diastolic blood pressure(DBP) greater or equal to 90-99-mmHg, 100 patients were randomized into two study groups using a table of random numbers. Group 1 received tab amlodipine (5 mg) and Group 2 received tab hydrocholrthiazide-amiloride (25 mg-2.5mg). Informed written consent was taken. The patients were followed on subsequent visits (6 in total) for five months and systolic and diastolic blood pressure was recorded carefully. All the data thus obtained were processed and analyzed using SPSS version 10.0. Mean and standard deviation (SD) were calculated for age, diastolic and systolic blood pressure. In group 1 the drop in mean SBP between first and last visit was 15.42 mm Hg. In group 2 the drop in mean SBP between first and last visit was 18.34 mm Hg. In group 1, the drop in mean DBP between first and last visit was 10.08 mm Hg. In group 2 the drop in mean DBP between first and last visit was 14.65 mmHg. Mean drop in SBP of both the groups were compared with each other and found to be significantly different (P=0.003). Similarly mean drop in DBP of both the groups were compared with each other and found to be significant statistically (P=0.001). Hydrochlorothiazide-Amiloride had significantly better antihypertensive effect than Amlodipine in patients of mild essential hypertension at the end of five months therapy. (author)
Primary Subject
Record Type
Journal Article
Journal
Pakistan Armed Forces Medical Journal; ISSN 0030-9648;
; v. 60(1); p. 37-41

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] The stability of captopril in powder papers under three different storage conditions was determined. Captopril 12.5-mg tablets were triturated with lactose to a final concentration of 2 mg of captopril in 100 mg of powder. A total of 240 powder papers were prepared and stored in class A prescription vials (80 papers), 002G plastic zip-lock bags (80 papers), and Moisture Proof Barrier Bags (80 papers). Immediately after preparation and at 1, 2, 3, 4, 8, 12, and 24 weeks of storage at room temperature, powder papers under each storage condition were reweighed and the contents were assayed for captopril concentration by a stability-indicating high-performance liquid chromatographic method. More than 90% of the initial captopril concentration was retained under all storage conditions during the first 12 weeks of the study. Captopril disulfide, a degradation product, was detected in one sample stored in a plastic zip-lock bag at 24 weeks. Captopril was stable for the entire 24-week period in powder papers stored in either the class A prescription vial or the Moisture Proof Barrier Bag. Captopril in powder papers is stable for at least 12 weeks when stored at room temperature under all three storage conditions
Primary Subject
Record Type
Journal Article
Journal
Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
AbstractAbstract
[en] Mammalian target of rapamycin complex (mTORC) regulates various cellular processes including proliferation, growth, migration and differentiation. In this study, we showed that mTORC1 regulates platelet-derived growth factor (PDGF)-induced phenotypic conversion of vascular smooth muscle cells (VSMCs). Stimulation of contractile VSMCs with PDGF significantly reduced the expression of contractile marker proteins in a time- and dose-dependent manner. In addition, angiotensin II (AngII)-induced contraction of VSMCs was completely blocked by the stimulation of VSMCs with PDGF. PDGF-dependent suppression of VSMC marker gene expression was significantly blocked by inhibition of phosphatidylinositol 3-kinase (PI3K), extracellular signal-regulated kinase (ERK), and mTOR whereas inhibition of p38 MAPK had no effect. In particular, inhibition of mTORC1 by rapamycin or by silencing of Raptor significantly blocked the PDGF-dependent phenotypic change of VSMCs whereas silencing of Rictor had no effect. In addition, loss of AngII-dependent contraction by PDGF was significantly retained by silencing of Raptor. Inhibition of mTORC1 by rapamycin or by silencing of Raptor significantly blocked PDGF-induced proliferation of VSMCs. Taken together, we suggest that mTORC1 plays an essential role in PDGF-dependent phenotypic changes of VSMCs. - Graphical abstract: Regulation of VSMC phenotype by PDGF-dependent activation of mTORC1. - Highlights: • The expression of contractile marker proteins was reduced by PDGF stimulation. • PDGF-dependent phenotypic conversion of VSMCs was blocked by inhibition of mTOR. • PDGF-induced proliferation of VSMCs was attenuated by inhibition of mTORC1. • mTORC1 plays a critical role in PDGF-dependent phenotypic conversion of VSMCs
Primary Subject
Source
S0006-291X(15)30021-8; Available from http://dx.doi.org/10.1016/j.bbrc.2015.05.097; Copyright (c) 2015 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.; Country of input: International Atomic Energy Agency (IAEA)
Record Type
Journal Article
Journal
Biochemical and Biophysical Research Communications; ISSN 0006-291X;
; CODEN BBRCA9; v. 464(1); p. 57-62

Country of publication
Reference NumberReference Number
INIS VolumeINIS Volume
INIS IssueINIS Issue
1 | 2 | 3 | Next |